#USA #New York #Series A #Neuropsychiatric #Gilgamesh Pharma

Gilgamesh Pharma Secures $60 Million in Series A Funding

Gilgamesh Pharma, a clinical-stage neuroscience company, has recently announced the successful closure of a $60 million Series A financing round. This oversubscribed funding reflects strong investor interest and highlights the promising nature of the company's clinical and preclinical programs aimed at treating psychiatric and neurological disorders.

This marks the first official capital raise for Gilgamesh Pharma, a company that spun out following the acquisition of Gilgamesh Pharmaceuticals and its neuropsychiatric compound, bretisilocin, by AbbVie in 2025. Leading this new venture is the same management team, alongside the retention of all programs not acquired by AbbVie, as well as the capital from the acquisition and a prior collaboration with AbbVie initiated in 2024.

The capital raised from this Series A financing is crucial for advancing Gilgamesh Pharma’s portfolio, which includes unique neuropsychiatric therapeutics characterized as new chemical entities (NCEs). This includes significant intellectual property rights pertaining to their compositions, which sets the foundation for future developments in psychiatric care.

Recently, the company reported encouraging results from its Phase 2 clinical trials of blixeprodil (GM-1020), an NMDA receptor antagonist designed for treating major depressive disorder (MDD). The phase 2 study recorded clinically significant improvements in MDD, and the company plans to move into late-stage clinical studies later this year.

Additionally, Gilgamesh Pharma is set to begin Phase 1 studies for its cardio-safe ibogaine analog, GM-3009, also slated for initiation this year. Furthermore, the collaboration with AbbVie continues to thrive, focusing on the development of neuroplastogen therapeutics for neuropsychiatric conditions. This collaboration not only enhances confidence in the company's capabilities but also furthers its innovative discovery platform.

This Series A round, led by Satori Neuro, included participation from both existing and new institutional investors, prominently featuring Prime Movers Lab, a previous investor in Gilgamesh Pharmaceuticals.

Jonathan Sporn, M.D., Founder and CEO of Gilgamesh Pharma, expressed confidence in the financing's potential to expedite the advancement of multiple programs within their pipeline while fostering ongoing discovery efforts addressing neuropsychiatric concerns. He remarked on the excitement surrounding the phase 2 results for GM-1020 and the continual progress of their broader pipeline, indicating a focus on momentum building.

Amy Kruse, General Partner and Chief Investment Officer of Satori Neuro, remarked on the company's groundbreaking approach, emphasizing the disciplined team and a portfolio capable of transforming mental health treatments. She noted that it's a privilege to lead this oversubscribed financing round, reaffirming commitment to help propel the development of blixeprodil and other critical programs.

The Future of Psychiatric Care

Gilgamesh Pharma focuses on innovation, developing new chemical entities aimed at redefining psychiatric treatment paradigms. Leading their pipeline is blixeprodil, an oral NMDA receptor antagonist that promises a rapid onset of action and robust efficacy, combined with a tolerable administration method. Expected to enter late-stage development in 2026, this program exemplifies the company’s vision to shift beyond mere symptom management.

The broader pipeline is dedicated to creating therapeutic avenues that result in meaningful improvements in patients' lives—an ambition that is clearly outlined in Gilgamesh Pharma's mission. Interested parties can explore more about their therapeutic pipeline on their official website. Follow Gilgamesh Pharma on professional networks like LinkedIn and X for the latest updates.